Laboratory parameters in patients receiving anti-CD20 treatment for ADAMTS13 relapse of TTP
| Blood parameter . | Before treatment (range) . | Remission (range) . | Δ Change (range) . | P . |
|---|---|---|---|---|
| Hemoglobin (g/L) | 133 (122-145) | 136 (125-150) | 2 (−2 to 8) | .19 |
| Reticulocytes (×109/L) | 60.2 (46.1-82.3) | 57.1 (45.0-79.8) | −0.7 (−12.3 to 9.3) | .41 |
| Platelets (×109/L) | 254 (203-297) | 272 (230-308) | 18 (0-43) | <.001 |
| Lactate dehydrogenase (IU/L) | 209 (179-243) | 191 (171-215) | −19 (−43 to 7) | .0008 |
| ADAMTS13 activity (%) | 9.2 (5.0-14.0) | 86.6 (66.2-100.5) | 76.0 (60.6-89.0) | <.001 |
| Absolute no. CD19+ lymphocytes (×109/L) | 0.2 (0.1-0.3) | 0 (0-0) | −0.1 (−0.3 to −0.1) | <.001 |
| CD19+ lymphocyte proportion (%) | 10.8 (6.5-16.4) | 0.1 (0-0.2) | −11 (−15.1 to 6.6) | <.001 |
| Blood parameter . | Before treatment (range) . | Remission (range) . | Δ Change (range) . | P . |
|---|---|---|---|---|
| Hemoglobin (g/L) | 133 (122-145) | 136 (125-150) | 2 (−2 to 8) | .19 |
| Reticulocytes (×109/L) | 60.2 (46.1-82.3) | 57.1 (45.0-79.8) | −0.7 (−12.3 to 9.3) | .41 |
| Platelets (×109/L) | 254 (203-297) | 272 (230-308) | 18 (0-43) | <.001 |
| Lactate dehydrogenase (IU/L) | 209 (179-243) | 191 (171-215) | −19 (−43 to 7) | .0008 |
| ADAMTS13 activity (%) | 9.2 (5.0-14.0) | 86.6 (66.2-100.5) | 76.0 (60.6-89.0) | <.001 |
| Absolute no. CD19+ lymphocytes (×109/L) | 0.2 (0.1-0.3) | 0 (0-0) | −0.1 (−0.3 to −0.1) | <.001 |
| CD19+ lymphocyte proportion (%) | 10.8 (6.5-16.4) | 0.1 (0-0.2) | −11 (−15.1 to 6.6) | <.001 |